A groundbreaking discovery in genetics has brought a glimmer of hope to Australians battling multiple sclerosis. This news comes at a time when the country is also making strides in cancer treatment, with immunotherapy now more accessible for those with advanced cancer. The latest PBS listings, dated March 1, 2026, offer a ray of sunshine for patients and their families.
But here's where it gets controversial: a nine-year wait for this listing raises questions about the efficiency of the system. Can we do better? And this is the part most people miss - the economic impact of obesity, a growing crisis in Australia, as highlighted in a recent report.
On March 2, 2026, another piece of good news emerged for Australians with aggressive lymphoma. Roche therapy has secured a PBS listing, offering a potential lifeline.
These developments showcase the progress and challenges in healthcare, leaving us with thought-provoking questions. Should we be satisfied with the pace of change, or is there room for improvement? What are your thoughts on the matter? Feel free to share your opinions in the comments below!
